Gossamer Bio layoffs (2026)
Gossamer Bio, a San Diego biotech, failed a Phase 3 trial for its lead drug seralutinib. It laid off 65 workers, almost half its staff.
The company cut clinical development staff and senior vice presidents.
Gossamer said it had enough cash to fund operations into early 2027.
Shows how a trial failure can trigger rapid layoffs in San Diego's biotech cluster.
